{
    "nct_id": "NCT05430009",
    "official_title": "Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Adult patients (â‰¥18 years of age)\n* Histologically or cytologically confirmed NSCLC with liver metastases\n* Eligible for immune checkpoint inhibitors per treating medical oncologist\n* Disease must be measurable per RECIST criteria\n* ECOG Performance status of 0 - 2\n* Adequate organ function per protocol.\n* Allowable prior therapy includes adjuvant durvalumab, prior radiotherapy outside the upper abdomen.\n* Patients must be willing and able to sign an informed consent form.\n* Participants of childbearing potential willing to undergo pregnancy test and use contraception per Appendix.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Liver tumor burden which cannot be targeted with SBRT per treating radiation oncologist\n* Presence of uncontrolled intercurrent illness or significant comorbidities precluding participation in a clinical study as determined by investigator\n* Diagnosis of underlying parenchymal end stage liver disease (cirrhosis) or biliary disease (primary biliary cirrhosis).\n* Other invasive malignancy active within 1 years, excluding in situ cancers\n* Presence of psychiatric or substance abuse disorders that would interfere with compliance or safety\n* Has a known history of active Bacillus Tuberculosis (TB), Hepatitis B or Hepatitis C infection\n* Has received a live (active) vaccine within 30 days of enrollment.\n* Active autoimmune disease that has required systemic treatment in the past 1 years aside from hormone replacement therapy (ie. thyroxine, insulin, or physiologic corticosteroid replacement therapy)\n* Baseline corticosteroid use (>10 mg prednisone daily or equivalent) at study entry\n* Pregnancy or breast feeding",
    "miscellaneous_criteria": ""
}